Baird downgraded Inari Medical (NARI) to Neutral from Outperform with a price target of $80, down from $81, after the company entered into a definitive agreement to be acquired by Stryker (SYK) for $80 per share in cash.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI: